Articles Tagged With:
-
CDC: Moderna COVID-19 Vaccine Causes Rare Anaphylactic Shock
From Dec. 21, 2020, to Jan. 10, 2021, the Vaccine Adverse Event Reporting System detected 10 cases of severe anaphylaxis after immunization with the Moderna COVID-19 vaccine, the Centers for Disease Control and Prevention reported. Ten cases coming out 4,041,396 first doses of the vaccine translates to 2.5 cases per million shots administered.
-
Overcoming COVID-19 Vaccine Hesitancy in Healthcare Workers
A striking 20% of nurses in the United States are refusing offers to be immunized with COVID-19 vaccine, according to the results of a national survey.
-
New CDC Director Takes Helm Amid Raging Pandemic
The Centers for Disease Control and Prevention has seen its pandemic response politicized and undermined over the past year, but a new director appointed by the Biden administration aims to restore the battered agency to its world-class standing.
-
Vaccines Threatened, Still Effective Against COVID-19 Variants
Current vaccines are holding against an emerging array of highly transmissible SARS-COV-2 variant strains, but researchers are warning that a somewhat literal “arms race” has begun between immunization science and relentless evolution.
-
Pediatric Drowning
Pediatric drowning events are associated with consequences varying from transient pulmonary symptoms to devastating neurologic disability. All acute care providers need to be prepared to diagnose and effectively manage a child with this type of injury.
-
Feds Redefine Who Can Handle COVID-19 Vaccine
HHS expands list of who can prescribe, dispense, and administer shots.
-
Biden Boosts ACA, Women’s Health
Executive actions aim to re-expand Obamacare access, protect reproductive health.
-
Why Is There Group Beating?
The ECG in the figure was obtained from a 40-year-old man with an irregular heartbeat. How would one interpret this rhythm?
-
Relugolix Tablets (Orgovyx)
Relugolix should be prescribed to adults with advanced prostate cancer.
-
Prophylactic PCI for Vulnerable Plaques
In this proof-of-concept trial, treatment of non-flow limiting vulnerable plaque by PCI with bioabsorbable stents resulted in no significant difference in lesion-related events compared with optimal medical therapy.